Forbes Talks to Ian Spatz on Future of Pharma After Health Decision
“What the Supreme Court Decision Means for Pharma”
June 28, 2012 – Manatt’s Ian Spatz, a senior advisor with Manatt Health Solutions, spoke to Forbes about how the Supreme Court’s decision to uphold the Affordable Care Act (ACA) will affect the biopharmaceutical industry.
Forbes reports that unless the health law is repealed, the decision doesn’t much change the ACA’s effect on pharmaceutical companies and biotechs. The industry presumably understood the fees and price cuts that it would face prior to the court ruling. In response, the industry had taken a proactive approach in dealing with the White House by offering a discount to seniors on the Medicare Part D prescription drug benefit.
“Today’s decision means that the impact of the ACA on pharma will change little,” said Spatz.
Spatz notes that nothing has really changed – that is, until or unless pharma decides backing repeal is the thing to do.
Read the article